# Selank (Russian Anxiolytic Peptide)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 3-4 (Russian approval + clinical trials)
**Risk Profile:** LOW
**Regulatory Status:** Approved in Russia (2009)

---

## What Is This?

Selank is an anti-anxiety peptide approved in Russia since 2009. What makes it remarkable: **it reduces anxiety WITHOUT sedation, cognitive impairment, tolerance, dependence, or withdrawal** — essentially all the problems with benzodiazepines. It works through GABA modulation (like benzos) but with a completely different side effect profile. Users describe it as "calm but alert" — you can drive, work, and function normally while anxiety is reduced. Administered as a nasal spray with effects lasting 4-6 hours.

---

## Categories

`Mood & Stress` · `Cognitive`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| GABA | Gamma-Aminobutyric Acid — the brain's main inhibitory (calming) neurotransmitter |
| GABA-A receptor | The receptor benzodiazepines and Selank both modulate |
| Tuftsin | Natural immune peptide that Selank is derived from |
| Enkephalins | Natural pain-relieving peptides that Selank helps preserve |
| Anxiolytic | Anxiety-reducing |
| N-Acetyl Selank | Modified version with enhanced stability and potency |
| Intranasal | Administered through the nose |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Molecular Weight | 751.9 g/mol |
| Origin | Modified Tuftsin fragment |
| Half-life | Minutes (effects persist hours) |
| Administration | Intranasal |
| Russian Approval | 2009 |

---

## Why Selank is Unique

| Parameter | Selank | Benzodiazepines |
|-----------|--------|-----------------|
| Anxiolytic efficacy | Yes | Yes |
| Sedation | **None** | Yes |
| Cognitive impairment | **None** | Yes |
| Tolerance | **None** | Yes |
| Dependence | **None** | Yes |
| Withdrawal | **None** | Yes |
| Safe to stop | **Yes** | No (taper required) |

**Clinical Significance:** Anti-anxiety without ANY benzodiazepine drawbacks.

---

## Clinical Evidence

Selank's evidence base differs from typical Western drug development but reflects substantial clinical use within the Russian medical system. The compound gained regulatory approval in Russia in 2009 following clinical trials demonstrating anxiolytic efficacy comparable to benzodiazepines but with a fundamentally different safety profile.

The pivotal trials examined patients with generalized anxiety disorder, comparing Selank to both placebo and standard anxiolytic medications. Results showed significant anxiety reduction on validated scales (Hamilton Anxiety Rating Scale and similar instruments) without the cognitive impairment, sedation, or dependence potential that characterizes benzodiazepine treatment. This combination — efficacy without major drawbacks — drove regulatory approval.

Perhaps more remarkable than the efficacy findings are the safety observations. Studies specifically examining tolerance development, physical dependence, and withdrawal symptoms found none. Patients could discontinue Selank abruptly without tapering, without rebound anxiety, without withdrawal symptoms. This distinguishes Selank categorically from benzodiazepines, where abrupt cessation after regular use can trigger seizures and severe rebound anxiety.

Cognitive function testing revealed no impairment during Selank treatment — and potentially some enhancement. This contrasts sharply with benzodiazepines, which consistently impair memory formation, psychomotor performance, and reaction time. Users maintained normal cognitive and motor function while experiencing anxiety reduction.

The optimizing effect on cognitive performance under stress appears genuine. Some studies suggest Selank not only reduces anxiety but enhances working memory and attention during stressful conditions, when anxiety typically impairs these functions. The mechanism may involve preventing anxiety-related cognitive disruption rather than directly enhancing cognition beyond baseline.

### Evidence Limitations

As with Semax, the primary limitation is geographic concentration of research. Most published studies originate from Russian institutions, with limited independent replication in Western settings. The methodology appears sound, and regulatory approval in a major pharmaceutical market carries weight, but Western clinicians and researchers typically prefer seeing effects replicated across diverse research environments.

Sample sizes in individual trials tend to be modest (dozens to low hundreds of patients rather than thousands). For a compound with benign side effect profile this is less concerning than for drugs with narrow therapeutic windows, but it does limit statistical power for detecting rare adverse events.

No published studies examine outcomes beyond several months of use. While absence of tolerance and dependence in shorter trials is reassuring, very long-term safety (years of continuous use) remains formally unstudied.

---

## Mechanism of Action

Selank's anxiolytic effects stem from a unique form of GABAergic modulation that diverges fundamentally from benzodiazepine pharmacology. While both compound classes enhance GABA-A receptor activity — the brain's primary inhibitory system — Selank accomplishes this without the sedation, cognitive impairment, tolerance, or dependence that define benzodiazepine use.

The mechanism involves positive allosteric modulation of GABA-A receptors, increasing their sensitivity to endogenous GABA without directly activating them. This preserves normal physiological regulation while enhancing the system's calming capacity. The result: anxiety reduction without the "drunk" feeling, memory impairment, or motor incoordination that benzodiazepines produce.

Selank also modulates enkephalin metabolism. Enkephalins are endogenous opioid peptides involved in pain perception, mood, and stress response. Selank inhibits enkephalinases — the enzymes that break down enkephalins — effectively increasing their stability and duration of action. This contributes to mood stabilization and stress resilience without the addiction potential of exogenous opioids.

The serotonergic system responds as well, with modulation of 5-HT receptors contributing to emotional stability and reduced anxiety. The compound's structure as a modified tuftsin fragment (an immune system peptide) grants it immunomodulatory properties, though the clinical significance of this effect in the context of anxiety treatment remains unclear.

What makes this mechanism profile remarkable is what's absent: no direct dopamine receptor activation (avoiding addiction potential), no histamine effects (avoiding sedation), no significant metabolic demands (avoiding tolerance). Selank modulates existing systems without overriding them, which may explain its lack of typical psychoactive drug side effects.

---

## Use Cases by Goal

### Generalized Anxiety Disorder

Generalized anxiety — the persistent, free-floating worry that colors daily experience — responds to GABA system modulation. Selank addresses this by enhancing GABAergic tone without the functional impairments benzodiazepines impose. Users can work, drive, think clearly, and maintain normal activities while experiencing reduced baseline anxiety.

The typical protocol involves 250-500mcg administered intranasally 2-3 times daily. Timing is flexible — morning dosing, split administration, or as-needed use all work depending on individual anxiety patterns. Effects begin within 10-20 minutes, providing relatively rapid relief without hours of delayed onset.

Duration of use varies. The standard Russian protocol suggests 10-14 day courses, but many users report successful continuous use without tolerance development. This differs dramatically from benzodiazepines, where tolerance emerges within weeks and cessation requires careful tapering. Selank can simply be stopped without withdrawal symptoms or rebound anxiety.

### Social and Performance Anxiety

Situational anxiety — job interviews, public speaking, social events, examinations — creates a distinct challenge. The anxiety is time-limited but potentially severe, and interventions that impair cognition or motor function defeat the purpose of managing the anxiety in the first place.

Selank's profile makes it particularly suitable here: anxiolytic effects without cognitive dulling, sedation, or visible impairment. The protocol involves 400-600mcg administered intranasally 30-60 minutes before the anxiety-provoking event. The effect is calming without creating a medicated appearance or feel. Users report being able to think clearly and perform normally while the edge of panic is removed.

This represents as-needed use rather than continuous administration, making it appropriate even for individuals without baseline anxiety disorders who face occasional high-stress situations.

### Stress Resilience and Daily Anxiety Management

For individuals experiencing chronic stress rather than clinical anxiety disorder, Selank offers a resilience-building approach. The rationale centers on stress adaptation — enhancing the nervous system's capacity to maintain equilibrium under ongoing demands.

The protocol is simpler: 400mcg once daily, often in the morning, administered over 2-6 week cycles. This provides consistent background anxiolytic effects without requiring frequent redosing. The cycling approach reflects conservative practice rather than demonstrated necessity — continuous use hasn't been associated with tolerance in available reports.

### Anxiety-Related Insomnia

When anxiety interferes with sleep initiation — the mind racing as you lie in bed, the inability to shut down worry and transition to rest — GABAergic modulation can facilitate the shift from wakefulness to sleep. Selank's calming without sedation becomes relevant here: it reduces the anxiety preventing sleep without forcing unconsciousness or creating next-day grogginess.

The protocol involves 400mcg administered intranasally before bed. This differs from sleeping pills in that Selank doesn't make you unconscious; it removes the obstacle to natural sleep initiation. The lack of next-morning impairment distinguishes it from benzodiazepine sleeping aids, which often leave users cognitively sluggish upon waking.

### Benzodiazepine Alternative for Mild-to-Moderate Anxiety

Perhaps Selank's most important use case is as an alternative to benzodiazepines in individuals with mild-to-moderate anxiety who want efficacy without accepting dependence risk. Benzodiazepines work, but they create tolerance, dependence, and withdrawal — often trapping users in long-term use they struggle to escape.

Selank offers anxiolytic effects without this trap. Protocols involve 250-500mcg administered 2-3 times daily, either continuously or cycled. Users can stop without tapering, without withdrawal, without rebound anxiety. This makes it suitable for individuals who need ongoing anxiety management but reject the dependence model.

Critical caveat: Selank is NOT appropriate for severe anxiety disorders, panic disorder, or as a replacement during benzodiazepine withdrawal. The latter requires medical supervision and careful tapering; Selank does not prevent benzodiazepine withdrawal seizures or manage acute withdrawal symptoms. This is for individuals seeking initial anxiety treatment without benzodiazepines, not for escaping existing benzodiazepine dependence.

### Combination with Semax: Balanced Cognitive Enhancement

The Semax-Selank combination addresses a fundamental problem in cognitive optimization: activation often produces anxiety, and calming often reduces performance. Selank provides anxiolysis and emotional stability. Semax provides stimulation, focus, and motivation. Together, they attempt to achieve "calm productivity" — sustained cognitive performance without mounting tension.

The typical protocol pairs equal doses, usually 400mcg of each compound administered together in the morning. Users describe being "focused but not wired" and able to sustain intense mental work without anxiety escalation. This stack is particularly popular during high-demand periods: examination preparation, intense projects, sustained intellectual work.

The mechanistic rationale is sound: GABAergic calming prevents the anxiety that dopaminergic activation might otherwise trigger, while dopaminergic drive prevents the reduced motivation that pure anxiolysis might produce. The goal is occupying the optimal zone between these states.

---

## Timing and Administration

### Intranasal Administration

1. Clear nasal passages
2. Tilt head slightly back
3. Administer drops/spray
4. Sniff gently (don't inhale hard)
5. Alternate nostrils for divided doses

### Why Intranasal

- Bypasses digestive degradation
- Rapid absorption to bloodstream and CNS
- Direct access via olfactory pathway
- Effects within 10-20 minutes

### Duration of Effects

| Parameter | Duration |
|-----------|----------|
| Onset | 10-20 minutes |
| Peak | 1-2 hours |
| Duration | 4-6 hours |

---

## User Experience Timeline

| Timeframe | Reported Effects |
|-----------|------------------|
| Day 1 | Immediate anxiolytic effect |
| Days 5-7 | Effects compound, anxiety reduction stabilizes |
| Week 2 | Full baseline anxiety reduction |
| Ongoing | No tolerance development reported |

---

## Dosing Summary

| Protocol | Dose | Frequency |
|----------|------|-----------|
| Standard | 250-500mcg | 2-3x daily |
| As-needed | 400-600mcg | Before stressful event |
| Daily maintenance | 400mcg | Once daily |
| With Semax | 400mcg each | Morning |

**Daily Maximum:** Do not exceed **1.5–2.0 mg/day total** (divided). Typical effective range is 500–1200 mcg/day.

### Forms Available

| Form | Notes |
|------|-------|
| Selank | Standard, well-studied |
| N-Acetyl Selank | Enhanced stability, slightly stronger |
| N-Acetyl Selank Amidate | Most potent form |

### Cycling (Russian Protocol)

- **Standard Russian regimen:** 0.3–0.9 mg/day for 14 days, repeat after 1–3 months
- **Continuous use option:** Many users stay at 0.3–0.5 mg/day long-term without reported tolerance
- No withdrawal symptoms reported upon cessation

---

## Side Effects

| Effect | Frequency |
|--------|-----------|
| Nasal dryness | Common |
| Mild relaxation | Expected |
| Headache | Occasional (high doses) |

**No sedation, no dependence, no withdrawal, no cognitive impairment.**

---

## Selank vs Semax

| Property | Selank | Semax |
|----------|--------|-------|
| Primary effect | Anxiolytic | Nootropic/stimulating |
| Feeling | Calming | Energized, focused |
| GABA effects | Strong | Minimal |
| Dopamine effects | Minimal | Strong |
| Best for | Anxiety | Cognition |
| Timing | Any time | Morning |
| Stack together | Yes—complementary |

---

## Contraindications

- Pregnancy/breastfeeding (no data)
- Severe immunological disorders
- Concurrent immunosuppressive therapy (theoretical)

---

## Limitations

1. **Not FDA approved** - Russian approval only
2. **Western sourcing variable** - Quality verification important
3. **Not for severe anxiety** - May need pharmaceuticals
4. **Not benzo replacement** for dependence/withdrawal

---

## References

1. Seredenin SB, et al. Anxiolytic effect of Selank. Zh Vyssh Nerv Deiat. 2002.
2. Zozulya AA, et al. Selank in generalized anxiety disorders. Zh Nevrol Psikhiatr. 2001.
3. Kozlovskii II, et al. Optimizing effect of Selank on memory. Bull Exp Biol Med. 2003.
4. Russian Ministry of Health registration documents.
